AstraZeneca Plc's Enhertu approved in the US for HER2+ solid tumours

AstraZeneca plc and Daiichi Sankyo's Enhertu has gained US approval for treating HER2-positive solid tumours, marking a significant advancement in cancer treatment.

Related Keywords

Brazil ,Australia ,Texas ,United States ,Singapore ,Ken Keller ,Dave Fredrickson ,Daiichi Sankyo ,University Of Texas Md Anderson Cancer Center ,Daiichi Sankyo Inc ,Astrazeneca ,Drug Administration ,Investigational Cancer Therapeutics ,Cancer Center ,Executive Vice President ,Oncology Business Unit ,Global Head ,Oncology Business ,Practice Guidelines ,Time Oncology Review ,Priority Review ,Breakthrough Therapy Designation ,Project Orbis ,